1,078 results match your criteria Lambert-Eaton Myasthenic Syndrome


Identification of a new SYT2 variant validates an unusual distal motor neuropathy phenotype.

Neurol Genet 2018 Dec 22;4(6):e282. Epub 2018 Oct 22.

Department of Neurology (N.I.M.-C., M.C., C.V., M.A.S.), University of Miami Miller School of Medicine FL; Department of Biology (Z.G., J.T.L.) and Department of Brain and Cognitive Sciences (Z.G., J.T.L.), The Picower Institute for Learning & Memory, Massachusetts Institute of Technology, Cambridge; and Department of Human Genetics (S.C., A.P.R., L.A., S.Z., M.A.S.), Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL.

Objective: To report a new missense mutation causing distal hereditary motor neuropathy and presynaptic neuromuscular junction (NMJ) transmission dysfunction.

Methods: We report a multigenerational family with a new missense mutation, c. 1112T>A (p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXG.0000000000000282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244021PMC
December 2018

Lambert-Eaton myasthenic syndrome developing post-diagnosis of small-cell lung cancer.

Intern Med J 2018 Dec;48(12):1541-1542

Sunshine Hospital, Western Health, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/imj.14128
Publisher Site
http://dx.doi.org/10.1111/imj.14128DOI Listing
December 2018
5 Reads

Repetitive Nerve Stimulation Test in Myasthenic Crisis.

Muscle Nerve 2018 Nov 29. Epub 2018 Nov 29.

Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Introduction: We are reporting our experience with the repetitive nerve stimulation (RNS) test in myasthenia gravis (MG) crisis.

Methods: The various parameters of the RNS tests in 26 patients with MG crisis were analyzed.

Results: In 18 (69%) patients, MG crisis is the first manifestation of MG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.26390DOI Listing
November 2018
1 Read

The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders.

J Neuroimmunol 2019 Jan 8;326:14-18. Epub 2018 Nov 8.

Department of Pathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham NG7 2UH, UK.

Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneoplastic disorders and controls. SOX2 antibodies were detectable in 61% of patients with LEMS-SCLC, and in other paraneoplastic disorders, such as opsoclonus-myoclonus and paraneoplastic cerebellar degeneration, only when there was an underlying SCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2018.11.003DOI Listing
January 2019
2 Reads

What is in the Neuromuscular Junction Literature?

J Clin Neuromuscul Dis 2018 Dec;20(2):76-84

Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA.

This update begins with myasthenia gravis and the roles of anti-agrin and cortactin antibodies. Regarding diagnosis, a report on repeated ice pack testing is highlighted as are several reports on the close correlation of electrodiagnostic testing with clinical features and the response to treatment. The incidence of head drop and associated clinical and ventilatory features are gleaned from a retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CND.0000000000000218DOI Listing
December 2018
1 Read

Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.

Mult Scler Relat Disord 2018 Oct 22;27:131-132. Epub 2018 Oct 22.

Wake Forest School of Medicine, Department of Neurology, One Medical Center Blvd, Winston Salem, NC 27157, USA. Electronic address:

Background: Alemtuzumab administration is known to cause secondary autoimmune disease but has not been associated with the development of neurologic autoimmune conditions. Lambert-Eaton myasthenic syndrome (LEMS) is caused by autoantibodies directed against calcium channels on the neuromuscular junction.

Case Report: We report a case of a patient with relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab who develop generalized weakness initially attributed to progression of MS but eventually determined to be due to LEMS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2018.10.015DOI Listing
October 2018

Autoimmune encephalitis with elevated N-type calcium channel antibodies as a multiple sclerosis mimic.

Mult Scler Relat Disord 2018 Sep 25;26:201-203. Epub 2018 Sep 25.

Department of Neurology, West Virginia University, 1 Medical Center Drive, Morgantown, WV 26505, USA.

Background: Voltage gated calcium channels (VGCC) are well-known targets for antibody-associated disease. Of the 5 VGCC subtypes, the most well-known is the P/Q subtype associated with Lambert-Eaton Myasthenic Syndrome (LEMS). However, this case focuses on the much less understood N-type calcium channel antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2018.09.028DOI Listing
September 2018
2 Reads

Stimulated single-fiber electromyography (sSFEMG) in Lambert-Eaton syndrome.

Clin Neurophysiol Pract 2018 13;3:148-150. Epub 2018 Aug 13.

I Division of Neurology and Neurophysiopathology, University of Campania "Luigi Vanvitelli", Naples, Italy.

Objective: To report the clinical features and the neurophysiological approach of a patient with Lambert-Eaton myasthenic syndrome (LEMS), highlighting the diagnostic role of the stimulated single fiber electromyography (sSFEMG).

Case Report: A 60-year-old woman presenting with the LEMS triad (proximal and axial weakness, autonomic dysfunction and areflexia) was evaluated by neurophysiological tests (electroneuromyography, repetitive stimulation test (TSR), voluntary and stimulated SFEMG). We reported: ) increase of compound muscle action potential (CMAP) amplitude (>60%) following brief isometric exercise compared to the rest (baseline); ) decremental/incremental response of CMAP amplitude at low- (3 Hz) and high-frequency (30 Hz) repetitive stimulation test (RST), respectively; ) increased neuromuscular jitter and blocking at voluntary single-fiber electromyography (vSFEMG); ) stimulation rate-dependent reduction of the neuromuscular jitter and blocking at sSFEMG. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S2467981X183002
Publisher Site
http://dx.doi.org/10.1016/j.cnp.2018.07.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134173PMC
August 2018
5 Reads

Lambert-Eaton Myasthenic Syndrome Associated With Extrapulmonary Small Cell Cancer Detected by 18F-FDG PET/CT.

Clin Nucl Med 2018 Sep;43(9):697-698

Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

A 46-year-old woman suffering from lower extremity weakness, dysarthria, dysphagia, dyspnea, and dry mouth was suspected of having Lambert-Eaton myasthenic syndrome based on the characteristic electromyographic abnormalities of right ulnar nerve, which demonstrated reduced resting compound muscle action potential amplitude and greater than 100% incremental change in high-frequency repetitive nerve stimulation. An F-FDG PET/CT was performed to detect the underlying neoplasm and revealed a retroperitoneal soft tissue mass with high F-FDG avidity in the left iliac fossa. The patient's symptoms were prominently relieved after the tumor resection, and the histopathology indicated a small cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002192DOI Listing
September 2018
2 Reads

Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes.

Semin Neurol 2018 06 16;38(3):344-354. Epub 2018 Jul 16.

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.

Autoimmune myasthenic syndromes are antibody-mediated disorders of the neuromuscular junction. Common antigenic targets are the acetylcholine receptor or muscle specific kinase (MuSK) in myasthenia gravis (MG) and the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. There is evidence that antibodies directed against other antigens such as low-density lipoprotein receptor-related protein 4 (LRP4) are also involved in MG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1660500DOI Listing
June 2018
11 Reads

Low specificity of voltage-gated calcium channel antibodies in Lambert-Eaton myasthenic syndrome: a call for caution.

J Neurol 2018 Jul 9. Epub 2018 Jul 9.

Department of Specialty Medicine, Neurohospitalist Service, Aultman Hospital, Neurohospitalist Office, 5th Floor, 2600 6th SW, Canton, OH, 44710, USA.

As testing for neuronal antibodies become more readily available, the spectrum of conditions potentially associated with these autoantibodies has been widening. Voltage-gated calcium channel antibodies (VGCC-Ab) are no exception to this trend. The significance of an elevated VGCC-Ab titer beyond its original clinicopathological correlate, Lambert-Eaton myasthenic syndrome (LEMS) remains undetermined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-018-8959-8DOI Listing
July 2018
4 Reads

Coexistence of myasthenia gravis and Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient: A case report.

Medicine (Baltimore) 2018 Jun;97(23):e10976

Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, P.R. China.

Rationale: Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are both neuromuscular junction diseases, and some controversy exists whether the 2 diseases occur at the same time.

Patient Concerns: We report a case that a patient with presentation of acetylcholine receptor (AChR) antibody positive MG and LEMS associated with small cell lung cancer (SCLC).

Diagnoses: The patient firstly suffered from fluctuant symptoms, including slurred speech, double eyelid ptosis, and weakness of limbs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000010976DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999448PMC
June 2018
17 Reads

Paraneoplastic syndromes in ophthalmology.

J Fr Ophtalmol 2018 May 18;41(5):e181-e185. Epub 2018 May 18.

Ophthalmology Service, CHU de Rennes, 35033 Rennes cedex, France. Electronic address:

Paraneoplastic syndromes involving the visual system are a heterogeneous group of disorders occurring in the setting of systemic malignancy. They are unrelated to local tumor invasion or metastasis and unexplained by nutritional, metabolic, infectious or iatrogenic causes. The presence of antibodies may aid in the diagnosis of a paraneoplastic syndrome, although this is not an absolute requirement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2018.03.002DOI Listing
May 2018
7 Reads

Coexistence of Lambert-Eaton myasthenic syndrome and autoimmune encephalitis with anti-CRMP5/CV2 and anti-GABAB receptor antibodies in small cell lung cancer: A case report.

Medicine (Baltimore) 2018 May;97(19):e0696

Department of Neurology, Affiliated Hospital of Jining Medical University, Jining.

Rationale: Autoimmune encephalitis and Lambert-Eaton myasthenic syndrome are classic paraneoplastic neurological conditions common in patients with small cell lung cancer.

Patient Concerns: The patient complained of tiredness, fluctuating recent memory loss, and inability to find his home. His family members reported a change in character, irritability, and paranoia. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201805110-0004
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000010696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959409PMC
May 2018
7 Reads

How to Spot Congenital Myasthenic Syndromes Resembling the Lambert-Eaton Myasthenic Syndrome? A Brief Review of Clinical, Electrophysiological, and Genetics Features.

Neuromolecular Med 2018 Jun 25;20(2):205-214. Epub 2018 Apr 25.

Department of Neuropediatrics and Muscle Disorders, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Congenital myasthenic syndromes (CMS) are heterogeneous genetic diseases in which neuromuscular transmission is compromised. CMS resembling the Lambert-Eaton myasthenic syndrome (CMS-LEMS) are emerging as a rare group of distinct presynaptic CMS that share the same electrophysiological features. They have low compound muscular action potential amplitude that increment after brief exercise (facilitation) or high-frequency repetitive nerve stimulation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12017-018-8490-1
Publisher Site
http://dx.doi.org/10.1007/s12017-018-8490-1DOI Listing
June 2018
16 Reads

Paraneoplastic Lambert-Eaton syndrome in a patient with disseminated metastatic cancer.

Cir Cir 2018 ;86(1):79-83

Medicina de Rehabilitación, Facultad de Medicina, Universidad de Guanajuato. León, Gto., México.

Background: Neurological paraneoplastic syndromes are rare, occur in 0.01% of all cancer patients; like part of them, the Lambert-Eaton syndrome is an autoimmune presynaptic disorder of neuromuscular transmission characterized by muscle weakness and neurovegetative dysfunction, and often associated with small cell lung cancer.

Case Report: A 72 years old female with a family history of lung cancer and leukemia, with 7 months of dry cough and 3 months with waist and pelvic muscle weakness, oropharyngeal dysphagia, dry mouth, chronic constipation and weight loss of 10 kg. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/CIRU.M18000006DOI Listing
November 2018
13 Reads

Lambert-Eaton Myasthenic Syndrome.

Neurol Clin 2018 May;36(2):379-394

Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 2012, Kansas City, KS 66160, USA.

Lambert-Eaton myasthenic syndrome is a paraneoplastic or primary autoimmune neuromuscular junction disorder characterized by proximal weakness, autonomic dysfunction and ariflexia. The characteristic symptoms are thought to be caused by antibodies generated against the P/Q-type voltage-gated calcium channels present on presynaptic nerve terminals and by diminished release of acetylcholine. More than half of Lambert-Eaton myasthenic syndrome cases are associated with small cell lung carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ncl.2018.01.008DOI Listing
May 2018
7 Reads

[P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].

Brain Nerve 2018 Apr;70(4):341-355

Department of Neurology and Strokology, Nagasaki University Hospital.

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease of the neuromuscular junction. Approximately 50-60% of patients with LEMS have a tumor, most often small cell lung cancer (SCLC), making LEMS a paraneoplastic neurological syndrome. In Japan, the clinical picture is a male: female ratio of 3:1; mean age, 62 years (17-80 years); and 61% of LEMS patients have SCLC (SCLC-LEMS), with the remainder of patients having no cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416201007DOI Listing
April 2018
3 Reads

Lambert-Eaton Myasthenic Syndrome Associated with Synchronous Double Cancer: A Combination of Small Cell Carcinoma of the Cervix and Breast Carcinoma.

Intern Med 2018 Aug 9;57(16):2409-2411. Epub 2018 Mar 9.

Division of Pathology, Shizuoka Cancer Center Hospital, Japan.

Lambert-Eaton myasthenic syndrome (LEMS) is most commonly associated with small cell lung carcinoma, while it is rarely associated with gynecological and breast carcinoma. We herein report a case of LEMS associated with synchronous double cancer, which was a combination of small cell carcinoma of the cervix and breast carcinoma. The early diagnosis and treatment of LEMS are important for achieving a good outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.0428-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148177PMC
August 2018
1 Read

Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features.

PLoS One 2018 8;13(3):e0193723. Epub 2018 Mar 8.

Department of Neurology, Seoul National University College of Medicine, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul National University Medical Research Council, Seoul, Republic of Korea.

Acquired myasthenia gravis (MG) is a prototype autoimmune disease of the neuromuscular junction, caused in most patients by autoantibodies to the muscle nicotinic acetylcholine receptor (AChR). There seem to be ethnic and regional differences in the frequency and clinical features of MG seronegative for the AChR antibody. This study aimed to describe the autoantibody profiles and clinical features of Korean patients with generalized MG seronegative for the AChR antibody. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193723PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843234PMC
June 2018
9 Reads

Pure Ocular Weakness as the Initial Manifestation of Lambert-Eaton Myasthenic Syndrome.

Cureus 2017 Dec 31;9(12):e2007. Epub 2017 Dec 31.

Neurology, University of Missouri Columbia.

Pure ocular presentation of Lambert-Eaton syndrome is not a common phenomenon. Such presentation poses significant diagnostic challenges and requires conscientious evaluation. In this review, we have described a case of a patient with pure ocular weakness, initially diagnosed as seronegative ocular myasthenia which on further evaluation was found to have ocular Lambert-Eaton myasthenic syndrome (LEMS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.2007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832401PMC
December 2017

Lambert-Eaton myasthenic syndrome: the 60th anniversary of Eaton and Lambert's pioneering article.

Arq Neuropsiquiatr 2018 Feb;76(2):124-126

Universidade Federal do Paraná, Hospital de Clínicas, Departamento de Clínica Médica, Serviço de Neurologia, Serviço de Doenças Neuromusculares, Curitiba PR, Brasil.

This historical review describes the contribution of Drs. Lee M. Eaton and Edward H. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0004-282X20170194DOI Listing
February 2018
1 Read

3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome: Concerns regarding presentation of previous studies.

Authors:
Shin J Oh

Muscle Nerve 2018 May 12;57(5):E130. Epub 2018 Feb 12.

Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.26091DOI Listing

3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.

J Clin Neurosci 2018 Apr 19;50:194-198. Epub 2018 Feb 19.

Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

3,4-Diaminopyridine (34DAP) is a presynaptic transmission enhancer. Its efficacy for Lambert-Eaton myasthenic syndrome (LEMS) and myasthenia gravis (MG) was demonstrated. However, there are cases sharing the characteristics of both disease and the effect of 34DAP in "gray zone" patients is sparse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2018.01.024DOI Listing

[A retrospective study of the effects of 3,4-diaminopyridine treatment in Lambert-Eaton myasthenic syndrome].

Rinsho Shinkeigaku 2018 Feb 31;58(2):83-87. Epub 2018 Jan 31.

Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.

In this independent clinical study, we analyzed retrospectively the clinical features of 9 cases (6 male and 3 female) of Lambert-Eaton myasthenic syndrome that were administered 3,4-diaminopyridine (3,4-DAP). Four cases showed no cancer and 5 cases had small cell lung carcinoma. Seven cases were positive for anti voltage-gated calcium channel antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5692/clinicalneurol.cn-001106DOI Listing
February 2018
5 Reads

A presynaptic congenital myasthenic syndrome attributed to a homozygous sequence variant in LAMA5.

Ann N Y Acad Sci 2018 Feb 28;1413(1):119-125. Epub 2018 Jan 28.

Department of Medicine and Rehabilitation, University of California Davis, Sacramento, California.

We report a severe defect of neuromuscular transmission in a consanguineous patient with a homozygous variant in the laminin α5 subunit gene (LAMA5). The variant c.8046C > T (p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nyas.13585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252105PMC
February 2018
7 Reads

Lambert-Eaton myasthenic syndrome and cerebellar ataxia: is Response to immunotherapy a clue to pathogenesis?

Muscle Nerve 2018 Jan 24. Epub 2018 Jan 24.

Department of Clinical Neurology, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.26079DOI Listing
January 2018

Retrospective study of paraneoplastic neurological syndromes in a Chinese Han population from Shandong, East China.

Int J Neurosci 2018 Sep 5;128(9):821-827. Epub 2018 Feb 5.

b Department of Neurology , General Hospital of Jinan Military Command , Jinan , China.

Objective: To analyze the clinical features, diagnostic strategies and therapeutic methods associated with paraneoplastic neurological syndromes.

Methods: A retrospective study of paraneoplastic neurological syndromes was performed at a single center in Shandong, East China. The medical records and follow-up data of 28 patients were intensively reviewed between February 2011 and December 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00207454.2018.1430693DOI Listing
September 2018
4 Reads

Paraneoplastic Inverse Myasthenic Syndrome as a Presentation of Bronchogenic Carcinoma.

J Assoc Physicians India 2017 Sep;65(9):98-99

Resident, Dept. of Medicine, INHS Asvini, Mumbai, Maharashtra.

Tumours may produce growth factors and cytokines responsible for signs and symptoms distant to the primary or metastatic site. This may be the first sign of a malignancy and its recognition may be critical for early cancer detection. Moreover, proper diagnosis spares the patient of extensive and expensive search for an alternate cause of the neurological dysfunction. Read More

View Article

Download full-text PDF

Source
September 2017
2 Reads

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

Muscle Nerve 2018 Apr 2;57(4):561-568. Epub 2018 Feb 2.

Jacobus Pharmaceutical Company, Princeton, New Jersey.

Introduction: 3,4-diaminopyridine has been used to treat Lambert-Eaton myasthenia (LEM) for 30 years despite the lack of conclusive evidence of efficacy.

Methods: We conducted a randomized double-blind placebo-controlled withdrawal study in patients with LEM who had been on stable regimens of 3,4-diaminopyridine base (3,4-DAP) for ≥ 3 months. The primary efficacy endpoint was >30% deterioration in triple timed up-and-go (3TUG) times during tapered drug withdrawal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.26052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900968PMC
April 2018
18 Reads

Calcium channel autoimmunity: Cerebellar ataxia and lambert-eaton syndrome coexisting.

Muscle Nerve 2017 Dec 22. Epub 2017 Dec 22.

Department of Neurology, College of Medicine, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota, 55905, USA.

Introduction: Neuronal calcium channel antibodies are a biomarker of Lambert-Eaton syndrome (LES) and cerebellar ataxia. We have encountered several patients with LES and cerebellar ataxia coexisting, and we sought to further define this association.

Methods: We reviewed records of patients at our institution with a diagnosis of "Lambert-Eaton syndrome" and "cerebellar ataxia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.26053DOI Listing
December 2017
8 Reads

Lambert-Eaton myasthenic syndrome with anti-acetylcholine receptor antibody and anterior mediastinal tumor.

J Gen Fam Med 2017 10 13;18(5):282-284. Epub 2017 Apr 13.

Department of Neurology Japanese Red Cross Medical Center Shibuya-ku TokyoJapan.

This report describes the case of a 65-year-old male who complained of muscular weakness of the legs with easy fatigability. Blood and imaging examinations showed positive anti-acetylcholine receptor antibody and an anterior mediastinal tumor (probably a thymic cyst), suggesting the diagnosis of myasthenia gravis (MG). However, neurological and electrophysiological examinations suggested the diagnosis of Lambert-Eaton myasthenic syndrome (LEMS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgf2.66DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689432PMC
October 2017
7 Reads

Paraneoplastic Disorders.

Authors:
Eric Lancaster

Continuum (Minneap Minn) 2017 12;23(6, Neuro-oncology):1653-1679

Purpose Of Review: Paraneoplastic neurologic syndromes target specific areas of the nervous system with pathogenic autoantibodies or T-cell responses. Each syndrome conveys a risk of particular tumors. Expanded paraneoplastic antibody testing has led to improved diagnosis but created challenges involving appropriate interpretation of test results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CON.0000000000000542DOI Listing
December 2017
5 Reads

The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome.

Eur J Pharm Sci 2018 Mar 28;114:24-29. Epub 2017 Nov 28.

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:

Background: Pharmaceutical compounding preparations, produced by (hospital) pharmacies, usually do not have marketing authorization. As a consequence, some of these pharmaceutical compounding preparations can be picked-up by a pharmaceutical company to obtain marketing authorization, often leading to price increases. An example is the 3,4-diaminopyridine slow release (3,4-DAP SR) tablets for Lambert-Eaton Myasthenic Syndrome (LEMS). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09280987173065
Publisher Site
http://dx.doi.org/10.1016/j.ejps.2017.11.025DOI Listing
March 2018
7 Reads

Paraneoplastic Lambert-Eaton Myasthenic Syndrome With Limbic Encephalitis: Clinical Correlation With the Coexistence of Anti-VGCC and Anti-GABAB Receptor Antibodies.

J Clin Neuromuscul Dis 2017 Dec;19(2):84-88

Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL.

Objective: To characterize Lambert-Eaton myasthenic syndrome and limbic encephalitis with coexistent voltage-gated calcium channel (VGCC) antibody and γ-aminobutyric acid (GABA) B receptor antibody.

Methods: Case study.

Results: A 57-year-old man presented with 6 months of weakness, unsteadiness, and vision difficulties. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00131402-201712000-0000
Publisher Site
http://dx.doi.org/10.1097/CND.0000000000000192DOI Listing
December 2017
10 Reads

Distinguishing Features of the Repetitive Nerve Stimulation Test Between Lambert-Eaton Myasthenic Syndrome and Myasthenia Gravis, 50-Year Reappraisal.

Authors:
Shin J Oh

J Clin Neuromuscul Dis 2017 Dec;19(2):66-75

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL.

Objective: To reappraise the distinguishing features of the repetitive nerve stimulation (RNS) tests in the abductor digiti quinti muscle between myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) 50 years after the 1965's Lambert seminal paper.

Methods: The various parameters of the RNS test were compared between 34 patients with LEMS and 140 patients with MG to assess their diagnostic sensitivity.

Results: RNS test was abnormal in all (100%) patients with LEMS and 76 (54%) patients with MG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CND.0000000000000190DOI Listing
December 2017
5 Reads

Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

Ann N Y Acad Sci 2018 Jan 10;1412(1):73-81. Epub 2017 Nov 10.

Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania.

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder caused by antibodies directed against the voltage-gated calcium channels that provide the calcium ion flux that triggers acetylcholine release at the neuromuscular junction. To study the pathophysiology of LEMS and test candidate therapeutic strategies, a passive-transfer animal model has been developed in mice, which can be created by daily intraperitoneal injections of LEMS patient serum or IgG into mice for 2-4 weeks. Results from studies of the mouse neuromuscular junction have revealed that each synapse has hundreds of transmitter release sites but that the probability for release at each one is likely to be low. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nyas.13512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790601PMC
January 2018
11 Reads

Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome Associated with Neuroendocrine Carcinoma of the Oropharynx.

Intern Med 2018 Feb 1;57(4):587-590. Epub 2017 Nov 1.

Department of Neurology, Osaka University Graduate School of Medicine, Japan.

Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome (PCD-LEMS) are usually associated with small-cell lung carcinoma (SCLC). PCD-LEMS with extrapulmonary non-SCLC tumors; however, has not been previously reported. A 78-year-old man presented with dysarthria, dysphagia, staggering gait, and lower extremity muscle fatigue. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/internalmedicine/57/4/5
Publisher Site
http://dx.doi.org/10.2169/internalmedicine.9333-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849558PMC
February 2018
23 Reads

A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis.

Vaccine 2017 11 6;35(46):6290-6296. Epub 2017 Oct 6.

Department of Neurology, Leiden University Medical Centre, The Netherlands.

Objective: To investigate the humoral immune response to and safety of a tetanus revaccination in patients with myasthenia gravis or Lambert-Eaton myasthenic syndrome.

Methods: A tetanus revaccination was administered to 66 patients. Before and 4weeks after revaccination a blood sample and clinical outcome scores were obtained. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2017.09.078DOI Listing
November 2017
18 Reads
3.620 Impact Factor

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports.

Medicine (Baltimore) 2017 Sep;96(38):e7839

aIRCSS Centro Neurolesi "Bonino-Pulejo", Neuromuscular Disease Laboratory bDepartment of Clinical and Experimental Medicine, University of Messina, Messina cDIBIMIS, University of Palermo, Palermo, Italy.

Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert-Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids.

Patient Concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (QMG) and activities of daily living scales, and autonomic nervous system involvement evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000007839DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617689PMC
September 2017
25 Reads

Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders.

Expert Opin Ther Targets 2017 10 24;21(10):949-958. Epub 2017 Aug 24.

a Division of Neurogenetics , Nagoya University Graduate School of Medicine , Nagoya , Japan.

Introduction: Signal transduction at the neuromuscular junction (NMJ) is compromised in a diverse array of diseases including myasthenia gravis, Lambert-Eaton myasthenic syndrome, Isaacs' syndrome, congenital myasthenic syndromes, Fukuyama-type congenital muscular dystrophy, amyotrophic lateral sclerosis, and sarcopenia. Except for sarcopenia, all are orphan diseases. In addition, the NMJ signal transduction is impaired by tetanus, botulinum, curare, α-bungarotoxin, conotoxins, organophosphate, sarin, VX, and soman to name a few. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14728222.2017.1
Publisher Site
http://dx.doi.org/10.1080/14728222.2017.1369960DOI Listing
October 2017
10 Reads

Adenocarcinoma of Lung Presenting as Lambert-Eaton Myasthenic Syndrome.

J Investig Med High Impact Case Rep 2017 Jul-Sep;5(3):2324709617721251. Epub 2017 Jul 14.

St. Francis Medical Center, Seton Hall University, Trenton, NJ, USA.

Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic neuromuscular junction disorder. LEMS presents with muscular weakness and fatigability, mainly involving the proximal lower limbs. There are 2 types of LEMS depending on the etiology: paraneoplastic and idiopathic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709617721251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521354PMC
July 2017
4 Reads

Erratum to: Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.

J Neurol 2017 Sep;264(9):1864

Fondazione IRCCS Istituto Neurologico, Via Giovanni Celoria, 11, 20133, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-017-8556-2DOI Listing
September 2017
5 Reads

Lambert-Eaton Myasthenic Syndrome with A Twenty-Three-Year Delay in Diagnosis.

Noro Psikiyatr Ars 2017 Jun 19;54(2):189-190. Epub 2017 Jan 19.

Department of Neurology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/npa.2016.12709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491672PMC
June 2017
3 Reads

Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function.

Clin Ther 2017 Jul 19;39(7):1360-1370. Epub 2017 Jun 19.

Catalyst Pharmaceuticals Inc, Coral Gables, Florida, USA.

Purpose: The purpose of this study is to evaluate safety, tolerability, and pharmacokinetic (PK) properties of amifampridine phosphate (Firdapse™) and its major inactive 3-N-acetyl metabolite in renally impaired and healthy individuals with slow acetylator (SA) and rapid acetylator (RA) phenotypes.

Methods: This was a Phase I, multicenter, open-label study of the PK properties and safety profile of amifampridine phosphate in individuals with normal, mild, moderate, or severely impaired renal function. Amifampridine phosphate was given as a single 10 mg (base equivalent) dose, and the plasma and urine PK properties of amifampridine and its 3-N-acetyl metabolite were determined. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01492918173066
Publisher Site
http://dx.doi.org/10.1016/j.clinthera.2017.05.353DOI Listing
July 2017
14 Reads

[Seronegative nonparaneoplastic Lambert-Eaton myasthenic syndrome].

Zh Nevrol Psikhiatr Im S S Korsakova 2017;117(5):77-80

Moscow City Health Department, Moscow Myasthenia Center, SFHI Municipal Clinical Hospital #51, Moscow, Russia; Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia.

The authors studied two patients with Lambert-Eaton myasthenic syndrome (LEMS) in whom the repeated examination did not find specific of LEMS P/Q type voltage-gates calcium channel autoantibodies. The results of clinical testing and electrophysiological examination showed the typical character of movement disorders with the absence of tendon reflexes and signs of disautonomia as well as a decrease in M-response amplitude and phenomena of decrement with low frequency- and increment with high frequency stimulation. Both patients revealed no signs of paraneoplastic process. Read More

View Article

Download full-text PDF

Source
http://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhi
Publisher Site
http://dx.doi.org/10.17116/jnevro20171175177-80DOI Listing
November 2018
3 Reads

History of electromyography and nerve conduction studies: A tribute to the founding fathers.

J Clin Neurosci 2017 Sep 16;43:54-60. Epub 2017 Jun 16.

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

The early development of nerve conduction studies (NCS) and electromyography (EMG) was linked to the discovery of electricity. This relationship had been concluded by observing the effect of applying electricity to the body of an animal and discovering that nerves and muscles themselves could produce electricity. We attempt to review the historical evolution of NCS and EMG over the last three centuries by reviewing the landmark publications of Galvani, Adrian, Denny-Brown, Larrabee, and Lambert. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2017.05.018DOI Listing
September 2017
7 Reads

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.

CPT Pharmacometrics Syst Pharmacol 2017 09 24;6(9):625-634. Epub 2017 Jul 24.

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Lambert-Eaton myasthenia (LEM) is a rare autoimmune disorder associated with debilitating muscle weakness. There are limited treatment options and 3,4-diaminopyridine (3,4-DAP) free base is an investigational orphan drug used to treat LEM-related weakness. We performed a population pharmacokinetic/pharmacodynamic (PK/PD) analysis using 3,4-DAP and metabolite concentrations collected from a phase II study in patients with LEM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/psp4.12218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613184PMC
September 2017
25 Reads
1 Citation